EPISODE · Jun 13, 2024 · 5 MIN
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
from Rheumnow Podcast · host Dr. Cush
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
What this episode covers
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitorLB0005 Izokibep IL17A nanobody inhibitorPOS0803 Vunakizumab, another IL17A inhibitorOP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
NOW PLAYING
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Jan 2, 2026 ·47m
Dec 21, 2025 ·46m